Epidermal Exosomes Guide

Overview

Parent Cell: Akira Epidermal Skin Cells differentiated from UCT-WJ-MSCs | Skin-specific regenerative exosomes for wound healing, scar remodeling, aesthetic skin rejuvenation, and chronic skin conditions

Related: Exosomes Overview • Epidermal Skin Cells

FOR RESEARCH USE AND INTERNATIONAL USE ONLY

Specs	Details
Source	Isolated from Akira Epidermal Skin Cells (differentiated from UCT-WJ-MSCs)
Growth Factors	EGF, KGF (FGF-7), VEGF-A, SCF
miRNA Cargo	miR-21, miR-146a
Identity Markers	CD9⁺/CD63⁺/CD81⁺ (pan-exosome tetraspanin identity)
Release Criteria	NTA-validated particle count per lot; ≥99% purity by differential ultracentrifugation
Storage	−20 °C; 4 °C post-thaw ≤ 72 hrs; do not refreeze
Immunogenicity	Non-immunogenic; cell-free with no nuclear material or MHC surface expression — no HLA matching required for allogeneic use
Manufacturing	cGMP, animal-product-free

Definition

What Are Exosomes?

Exosomes are nanoscale extracellular vesicles (40–150 nm) formed by inward budding of endosomal multivesicular bodies (MVBs) and released upon MVB fusion with the plasma membrane. They carry a protected cargo of mRNAs, miRNAs, proteins, lipids, and signaling molecules from their parent cell, delivering this molecular payload to recipient cells with high specificity and efficiency. Unlike the parent cell, exosomes carry no nuclear material and cannot self-replicate — providing a cell-free therapeutic profile with superior safety and stability characteristics.

Process

Mechanism of Action & Molecular Cargo

Re-Epithelialization Acceleration: EGF, KGF (FGF-7), and TGF-α cargo activates keratinocyte EGFR, driving migration and proliferation for wound closure — MSC-exosome acceleration of re-epithelialization is established in full-thickness wound models generally.^[1]

Collagen Remodeling: TGF-β inhibitor miRNAs (miR-21) combined with EGF-driven fibroblast stimulation achieve optimal collagen I:III ratio — reducing hypertrophic scarring while maintaining wound strength.

Angiogenesis: VEGF-A delivery to wound bed promotes capillary ingrowth, essential for dermal matrix remodeling and wound tissue oxygenation.

Anti-Inflammatory: miR-146a suppresses macrophage M1 activation, reducing chronic wound inflammation that impairs healing in diabetic ulcers and chronic wounds.

Anti-Hyperpigmentation: Melanocyte-suppressing KGF/SCF balance modulation reduces post-inflammatory hyperpigmentation and normalizes melanin distribution.

Biomarkers

Key Molecular Cargo

Molecule / miRNA	Therapeutic Function
EGF / KGF (FGF-7)	Keratinocyte migration and proliferation; re-epithelialization
VEGF-A	Wound bed angiogenesis
miR-21	TGF-β suppression → anti-fibrotic; hypertrophic scar prevention
miR-146a	Anti-inflammatory; M1 macrophage suppression in wound bed
SCF / KGF (melanocyte modulation)	Hyperpigmentation correction via melanocyte activity normalization
Collagen I/III mRNA induction	Fibroblast collagen quality optimization

Applications

Potential Applications

Burns & Scalds — accelerated re-epithelialization
Diabetic Ulcers — chronic wound closure
Acne Scars — collagen remodeling, texture improvement
Hyperpigmentation — melanocyte normalization
Wrinkle Reduction / Skin Aging — collagen and elastin stimulation
Post-Microneedling / Post-Laser Recovery — enhanced healing
Stretch Marks (Striae) — dermal matrix regeneration
Lichen Sclerosus — anti-inflammatory, tissue restoration
Psoriasis — keratinocyte proliferation normalization

These are experimental use cases, provided as a scientific reference for researchers. Except where noted, they did not use Akira Biotech materials, and results may not be reproducible with ours. Akira Biotech supplies laboratory reagents for research use only. Our products are NOT approved by FDA or any regulatory authority and are not for use in or on humans.

Evidence

Clinical & Preclinical Evidence

A 2025 systematic review of MSC-exosome-based dermatological treatments (10 human studies) confirmed significant scar remodeling, pigmentation improvement, and skin quality enhancement — with excellent safety and no adverse events across all indications.^[2]

A study reported in Signal Transduction and Targeted Therapy (2024) associated MSC-derived EVs with improved tissue remodeling, fibroblast function, and dermal repair in aging skin; this specific study is not tied to a single verifiable published source in Akira's reference set and should be treated as directionally supportive rather than a confirmed citation.

A retrospective case series (June 2023–November 2024, n=4, follow-up to 10 months) reported significant scar improvement, enhanced elasticity, and improved hydration using an exosome-based wound and scar treatment^[3] — note this case series used a plant-derived exosome source rather than an MSC-derived one, so it is included as adjacent supportive evidence for the exosome delivery modality rather than as direct evidence for this MSC-derived product.

Multiple systematic reviews of MSC exosome skin wound healing confirm consistent anti-inflammatory, pro-angiogenic, and matrix-remodeling effects across wound types.^[4]^[5] Combination studies pairing MSC-derived exosomes with laser or microneedling delivery report improved acne scar outcomes^[6], skin rejuvenation after micro-needling^[7], and facial pore/texture improvement^[8] — supporting the aesthetic application set above. General cutaneous wound healing benefit of MSC-derived exosomes is further supported by a dedicated mechanistic review^[9] and by exosome-loaded hydrogel wound healing research.^[1]

Epidermal Exosomes